Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2003-08-20
2010-10-26
Royds, Leslie A. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S315000, C514S364000
Reexamination Certificate
active
07820679
ABSTRACT:
The use of N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide, or a pharmaceutically acceptable salt thereof, in the treatment of cancer and/or pain in a warm blooded animal such as man is described.
REFERENCES:
patent: 5464853 (1995-11-01), Chan et al.
patent: 5514691 (1996-05-01), Chan et al.
patent: 5843902 (1998-12-01), Garnick et al.
patent: 5866568 (1999-02-01), Bradbury et al.
patent: 2002/0055457 (2002-05-01), Janus
patent: 2003/0092757 (2003-05-01), Singh et al.
patent: 2005/0014769 (2005-01-01), Osswald et al.
patent: 510526 (1992-10-01), None
patent: 526708 (1993-02-01), None
patent: 558258 (1993-09-01), None
patent: 569193 (1993-11-01), None
patent: 640596 (1995-03-01), None
patent: 682016 (1995-11-01), None
patent: 749964 (1996-12-01), None
patent: 1 256344 (2002-11-01), None
patent: 1 424 080 (2004-06-01), None
patent: 2295616 (1996-06-01), None
patent: WO 94/27979 (1994-12-01), None
patent: WO 95/26957 (1995-10-01), None
patent: WO 96/09818 (1996-04-01), None
patent: WO 96/40681 (1996-12-01), None
patent: WO 98/40332 (1998-09-01), None
patent: WO 99/48530 (1999-09-01), None
patent: WO 99/56761 (1999-11-01), None
patent: WO 00/21509 (2000-04-01), None
patent: WO 00/36918 (2000-06-01), None
patent: WO 00/67024 (2000-11-01), None
patent: WO 01/00198 (2001-01-01), None
patent: WO 01/44239 (2001-06-01), None
patent: WO 01/60370 (2001-08-01), None
patent: WO 01/91736 (2001-12-01), None
patent: WO 02/11713 (2002-02-01), None
patent: WO 02/49630 (2002-06-01), None
patent: WO 02/069906 (2002-09-01), None
patent: WO 02/074034 (2002-09-01), None
patent: WO 02/080960 (2002-10-01), None
patent: WO 02/085351 (2002-10-01), None
patent: WO 03/006041 (2003-01-01), None
patent: WO 03/009805 (2003-02-01), None
patent: WO 03/015820 (2003-02-01), None
patent: WO 03/039539 (2003-05-01), None
patent: WO 03/045434 (2003-06-01), None
patent: WO 2004/032922 (2004-04-01), None
patent: WO 2004/035057 (2004-04-01), None
patent: WO 2005/023264 (2005-03-01), None
patent: 2005/063735 (2005-07-01), None
patent: WO 2005/080403 (2005-09-01), None
patent: 2006/056760 (2006-06-01), None
patent: 2007/010235 (2007-01-01), None
Hsu et al. “ET-1 Expression and Growth Inhibition of Prostate Cancer Cells: A Retinoid Target with Novel Specificity”. Cancer Research. 1998; 58:4817-4822.
Bradbury, Robert, H et al, “New Non-peptide Endothelin-A Receptor Antagonists: Synthesis, Biological Properties, and Structure-Activity Relationships of 5-(Dimethylamino)-N-pyridyl-, -N-pyrimidinyl, -N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides”, J Med Chem, May 14, 1997, 996-1004, 40.
Brooks N. et al, “ZD4054—a specific endothelin-A receptor antagonist providing hope for treatment of HRPC”, 4th PacRim Breast and Prostate Cancer Meeting. British Columbia, Canada, Aug. 12-16, 2008. abstract.
Carducci M.A. et al, “Targeting bone metastasis in prostate cancer with endothelin receptor antagonists”, Clin Cancer Res, 2006, 6296s-6300s, 12.
Carducci, M.A. et al, “The Endothelin-A Receptor Antagonist Atrasentan (ABT-627) Delays Clinical Progression in Hormone Refractory Prostate Cancer: a Multinational, Randomized, Double-Blind, Placebo-Controlled Trial”, Asco Abstracts 2001.
Carragher N. et al “Application of 3-dimensional (3D) in vitro invasion assays demonstrate anti-invasive activity of the specific endothelin-A (ETA) receptor-antagonist ZD4054 when combined with the novel Src/Abl inhibitor AZD0530”NCRI. Birmingham, UK, Oct. 5-8, 2008; abst B77.
Chiao, J.W. et al, “Endothelin-1 from Prostate Cancer Cells is enhanced by bone contact which blocks osteoclastic bone resorption”, British Journal of Cancer, 2000, 360-365, 83(3).
Chirgwin, J.M. et al, “Tumor-bone cellular interactions in skeletal metastases”, J Musculoskel Neuron Interact, 2004, 308-318, 4(3).
Clarkson-Jones J. et al, “Metabolism of [14C]-ZD4054 in healthy volunteers”, Drug Metab Rev, 2008, 206, 40 (Suppl 3) (Abstract 283).
Clarkson-Jones J. et al, “Metabolism of [14C]-ZD4054 in healthy volunteers”, poster, ISSX—15th North American Regional Meeting, San Diego, USA, Oct. 12-16, 2008.
Curwen J et al, “The impact of ZD4054, a specific endothelin-A receptor antagonist, on tumor blood supply, invasion and the bone microenvironment” Mol Cancer Ther, 2007;6(12) Suppl II:abst A272.
Curwen J et al, “The impact of ZD4054, a specific endothelin-A receptor antagonist, on tumor blood supply, invasion and the bone microenvironment”, AACR-NCI-EORTC, San Francisco, USA, Oct. 22-26, 2007. Poster.
Curwen, J. et al, “The specific endothelin A receptor antagonist ZD4054 reduces tumour-induced angiogenesis in a preclinical model”, 10th International Conference on Endothelin (ET-10). Bergamo, Italy, Sep. 16-19, 2007; oral presentation.
Curwen, J. et al, “The specific endothelin A receptor antagonist ZD4054 reduces tumour-induced angiogenesis in a preclinical model”, 10th International Conference on Endothelin (ET-10). Bergamo, Italy, Sep. 16-19, 2007; poster.
Dawson N. et al, “Impact of the specific endothelin-A (ETA) receptor antagonist ZD4054 on overall survival and bone metastasis in patients with hormone-resistant prostate cancer: results of a Phase II trial”, Current Treat Options Oncol 2008; 105-107, 9(Suppl 1).
Dawson N. et al, “Impact of the specific endothelin-A (ETA) receptor antagonist ZD4054 on overall survival and bone metastasis in patients with hormone-resistant prostate cancer: results of a Phase II trial”, oral presentation, Chemotherapy Foundation Symposium, New York, USA, Nov. 4-7, 2008.
Dawson N. et al,“Impact of the specific endothelin A receptor antagonist ZD4054 on overall survival and bone metastasis in patients with hormone-resistant prostate cancer: results of a Phase II trial”, ASCO GU Congress, San Francisco, USA Feb. 14-16, 2008, Genitourinary Cancers Symposium Proceedings 2008;abst 7.
Dawson N. et al,“Impact of the specific endothelin A receptor antagonist ZD4054 on overall survival and bone metastasis in patients with hormone-resistant prostate cancer: results of a Phase II trial”, ASCO GU Congress, San Francisco, USA Feb. 14-16, 2008, poster.
Dingemanse, J. et al, “Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects”, Br J Clin Pharmacol, Apr. 28, 2002, 355-362, 53.
Fizazi K.et al, “The Effects of Endothelin-1 and Abt-627, and Endothelin-1 Antagonist, in an in Vitro Model of Bone Metastases from Prostate Cancer”, Asco Abstracts 2001.
Godara G. et al, “Distinct Patterns of Endothelin Axis Expression in Primary Prostate Cancer”, Urology, 2007, 209-215, vol. 70(1).
Godara G. et al, “Role of Endothelin Axis in progression to Aggressive Phenotype of Prostate Adenocarcinoma”, The Prostate, 2005, 27-34, 65.
Gross-Goupil M. et al, “Integrating Molecular Oncology into Therapeutic Strategies for Prostate Cancer”, European Urology Supplements, 2009, 114-119, 8.
Growcott J. et al “ZD4054—A small-molecule, specific endothelin-A receptor antagonist: providing hope for patients with hormone-resistant prostate cancer”, AZ-Manchester Cancer Research Centre Showcase. Manchester, UK, Sep. 22, 2008.
Growcott J. et al, “Anti-invasive activity of the specific endothelin-A receptor (ETAR) antagonist, ZD4054, in A673 rhabdomyosarcoma cells”, 10th International Conference on Endothelin (ET-10). Bergamo, Italy, Sep. 16-19, 2007. Poster.
Growcott J. et al, “Anti-invasive activity of the specific endothelin-A receptor (ETAR) antagonist, ZD4054, in A673 rhabdomyosarcoma cells”, 10th International Conference on Endothelin (ET-10). Bergamo, Italy, Sep. 16-19, 2007. Oral Presentation.
Growcott J.W. et al, “Phenotypic in vitro differentiation of the spe
Ashford Marianne Bernice
Barrass Nigel Charles
Boyle Francis Thomas
Hughes Andrew Mark
Johnstone Donna
AstraZeneca AB
Royds Leslie A.
LandOfFree
N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-′1,3,4-oxadi... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-′1,3,4-oxadi..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-(-3-methoxy-5-methylpyrazin-2-yl)-2-(4-′1,3,4-oxadi... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4162138